Cost-effectiveness of biological treatment sequences for fistulising Crohn’s disease across Europe

DOI: 10.1177/2050640617708952

Keywords: Cost-effectiveness, biosimilar-infliximab, infliximab, adalimumab, vedolizumab, biosimilar, fistulising Crohn’s disease

Full-Text   Cite this paper   Add to My Lib

Abstract:

Full-Text